CBX

China Biotech XYZ (CBX) is a platform dedicated to providing competitive intelligence services in the pharmaceuticals. Meet us

[CBX @CNBioXYZ]

China NMPA introduces new drug data protection. Innovative drugs get 6 yrs, 505(b)(2)-type drugs 4 yrs, generics shorter or none. Aligns China closer to US-style exclusivity. #DataProtection #FDA #NMPA #Exclusive

[CBX @CNBioXYZ]

Pfizer quietly terminated its PD-L1 ISAC, PF-08046037. No safety signal, no efficacy concern — just strategy.
What stays:
— Sasanlimab (PD-1, ph3 data in bladder cancer)
— PF-08046054 (PD-L1 MMAE ADC, pivotal)
— SSGJ-707 (PD-1/VEGF bispecific, in-licensed)
$PFE $MRK $BMY $SMMT

[CBX @CNBioXYZ]

Lilly drops the Nectin-4 ADC (LY4101174) with an enrollment of 143 globally. $LLY $PFE #CTR20253122

[CBX @CNBioXYZ]

Astellas Pharma has terminated the first-in-human study (NCT06544642) of its STING inhibitor ASP5502—an AI-derived PCC that moved from design to clinic in just 7 months. Speed is improving, but translation remains the real bottleneck.

[CBX @CNBioXYZ]

Merck has discontinued development of the PARP1i M9466 (HRS-1167), which it had licensed from Hengrui. In a Ph1 study evaluating the combination with irinotecan in CRC, the program encountered DLTs. Against this backdrop, the planned expansion into SCLC was not pursued further.

[CBX @CNBioXYZ]

Regeneron Pharmaceuticals has discontinued the Phase 2 NATRIX-SBP study (NCT06833190) evaluating REGN5381 in uncontrolled hypertension. The trial enrolled 34 pt before termination.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit. $REGN $NVS $LLY

[CBX @CNBioXYZ]

Merck Initiates Phase 1 Trial (NCT07089784) of Oral MK-2828 (GLP-1?) in Patients with T2DM $MRK #Hansoh $NVO $LLY

[CBX @CNBioXYZ]

CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028. Tables might turn — will CTTQ's Anlotinib be next? $HCM $TAK

[CBX @CNBioXYZ]

Bayer Files HER2i BAY 2927088 NDA in China. #Bayer #HER2 #China

[CBX @CNBioXYZ]

Novartis Seeks IND Clearance for PKN605 in China. #Novartis #PKN605 #AF $NVS

[CBX @CNBioXYZ]

BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns. #Bayer #Astellas #ASP1570 #BAY2965501

[CBX @CNBioXYZ]

BMS has submitted its first IND application in China for BMS-986340, an investigational anti-CCR8 monoclonal antibody. $BMY $ZLAB $ONC

[CBX @CNBioXYZ]

Puhe Biopharma Submits IND Application in China for WRN Inhibitor PH027 Targeting MSI-H Tumors. $NVS $GSK $RHHBY

[CBX @CNBioXYZ]

The next generation anti-nectin-4 ADC LY4052031 study (NCT06465069) is on hold because Eli Lilly called it off. It's about advanced urothelial or other solid tumors. $LLY $PFE $MRK
https://t.co/AHd7mCxqjM

[CBX @CNBioXYZ]

Hengrui Pharmaceuticals files for the Hong Kong IPO. https://t.co/9JBUolTJo3

[CBX @CNBioXYZ]

Mabwell (Shanghai) Bioscience has applied for an IPO in Hong Kong.

[CBX @CNBioXYZ]

Due to a business decision, Astellas terminated the phase 1 study of CD20 autologous convertible CAR-T ASP2802.
#NCT06248086
#Xyphos https://t.co/DHPHizta27

[CBX @CNBioXYZ]

Haixi Pharmaceuticals files for Hong Kong IPO.

[CBX @CNBioXYZ]

BMS initiates a phase 1/2 trial of BMS-986490 (anti-CEACAM5) in the pts with solid tumor. #NCT06730750 $BMY $SNY

[CBX @CNBioXYZ]

Innogen Pharmaceutical files for HK IPO. #GLP1

Notes: SciWind filed BLA for Ecnoglutide, XW003 in November.